Long-Term, Patient-Level Analysis of Radiofrequency Renal Denervation in the SYMPLICITY Clinical Trial Program
Authors' conclusion
Modeling suggested patients have durable BP reductions following RDN, with a steep immediate reduction followed by a steady reduction through 3 years.
Study context
- Population
- Patients treated with the Symplicity renal denervation (RDN) system in the SYMPLICITY Clinical programpatients treated with the Symplicity RDN system included in the mixed model
- Participants
- 4,155 patients
- Outcome
- Longitudinal office and 24-h ambulatory SBP changes, adjusted for antihypertensive (AH) medication effects
- Follow-up
- Through 36 months
Methodological detailslinear mixed models
- Linear mixed models
Main finding
As reported in the abstract
- Biphasic: steep reduction after RDN through the first 6 months followed by continuous and steady reductions in office and 24-h systolic BP (SBP) and diastolic BP (DBP) through 36 months
Further findings
Baseline SBP and subsequent SBP reduction
- Higher baseline office systolic or 24-h ambulatory SBP correlated with greater reductions through follow-up in office and 24-h SBP, respectively
Patient characteristics associated with blood pressure (BP) reduction
- Atrial fibrillation and type 2 diabetes emerged as statistically significant covariates associated with greater office systolic and office and 24-h diastolic BP reductions, respectively
Baseline characteristics
- Mean age
- 60 ± 12 years
- Female
- 40.4%
Original publication
Long-Term, Patient-Level Analysis of Radiofrequency Renal Denervation in the SYMPLICITY Clinical Trial Program. JACC Adv. Published 21 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it